Energy and AI, Volume 11, January 2023
This article supports SDGs 7,9 and 11 by proposing that the real-time online analysis, data integration, and prediction of future status, monitoring, decision-making, and self-healing of the power grid can be achieved, providing high security, reducing the risk of power grid accidents, and serving multiple fields of producers, consumers, and the entire country.
Elsevier,
Trends in Immunology, Volume 44, January 2023
Due to multiple cellular blocks in transcription, HIV-1 latency can only be reversed in a minor fraction of infected but potentially virus-producing CD4+ T cells from infected patients. New insights into the regulation of transcription elongation factor P-TEFb as a crucial rate-limiting step in the emergence of HIV-1 from latency may help design more effective latency reversal agents during HIV-1 infection.
Elsevier,
Antiviral Research, Volume 209, January 2023
This review supports SDG3 by detailing the current fundamental knowledge of HDV lifecycle and review antiviral treatments under development against this virus, outlining their respective mechanisms-of-action. Finally, it describes the antiviral effect these compounds are showing in ongoing clinical trials, discussing their promise and potential pitfalls for managing HDV infected patients.
Elsevier,
Virology, Volume 578, January 2023
This article supports SDG 3 by providing accurate folds of Hepatitis E Virus' five domains. The work highlights that there is no canonical protease encoded in pORF1 and that flexibility in several functionally important regions rather than proteolytic processing may serve to regulate HEV RNA synthesis
Elsevier,
Virus Research, Volume 323, 2 January 2023
This article supports SDG 3 as chronic hepatitis B (HBV) and C virus (HCV) infections represent significant public health issues internationally. This paper aims to evaluate the efficacy of hepatitis B vaccination in HCV-related chronic liver disease and identify possible factors that may contribute to hypo-responsiveness in those patients.
Elsevier,
Vaccine, Volume 41, 27 January 2023
This Article supports SDG 3 as the results show that two doses of the HEV 239 vaccine produces broad and likely functional immune responses against HEV that remain for at least two years. The safety profile was acceptable and a phase four study of HEV 239 in rural Bangladesh is feasible.
